Resources from the same session
57O - A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors
Presenter: Aaron Lisberg
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
58O - Clinical efficacy, safety, and PK/PD from the first in human study of BM201, a TLR7/8 agonist
Presenter: Rutian Li
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Abstract
Invited Discussant 57O and 58O
Presenter: Aaron Tan
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Slides
Webcast
478O - Updated results of oral PD-L1 inhibitor ABSK043 in advanced solid tumor patients (pts) from a phase I study
Presenter: Shun Lu
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Abstract
59O - A first-in-human, phase I study of BPI-371153, a novel small-molecule PD-L1 inhibitor, in advanced solid tumors or recurrent/refractory (r/r) lymphoma
Presenter: Jianliang Yang
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Invited Discussant 478O and 59O
Presenter: Stefan Symeonides
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session: Developmental and precision medicine
Resources:
Webcast